|
|
|
LifeScienceHistory.com - Check us out on Instagram
Texas Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing TexasLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Repros Therapeutics Inc.
| | | Phone: | (281) 719-3400 | Fax: | (281) 719-3446 | Year Established: | 1987 | Ticker: | RPRX | Exchange: | NASDAQ | Main Contact: | Larry Dillaha, M.D., President & CEO | | Other Contacts: | Patrick Fourteau, Chairman Joachim F. Wernicke, Ph.D., M.D., CMO Jaye Thompson, Ph.D., Senior VP, VP Clinical & Regulatory Ronald D. Wiehle, Ph.D., VP, R&D Katherine A. Anderson, C.P.A., CFO
| | Company Description | Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. Their lead drug, Proellex®, is a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. Their second product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. On Dec. 12, 2017, Repros Therapeutics announced it has entered into a definitive agreement under which Allergan will acquire Repros for a cash payment of $0.67 per share. The Company's Board of Directors has unanimously approved the transaction. | |
|
|
|
|
|